Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 360 participants.
Also called NCT01406717
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; quadruple masking; primary purpose treatment
- Phase
- Phase 3
- Enrolled
- 360 participants
- Sponsor
- Sun Pharmaceutical Industries Limited
- Registry
-
NCT01406717
-
- Start date
- (registry gives no type)
- Primary completion
- (actual)
- Completion
- (actual)
- Results first posted
- Countries
- India
- Registry status
- Completed
Technical summary
Registry record NCT01406717. Randomized; quadruple masking; primary purpose treatment. Start 2013-03-01 (registry gives no type); primary completion 2015-11-04 (actual). Results posted on 2019-11-01.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Safety and Efficacy of SPIL1033 in Subjects With Type 2 Diabetes Mellitus
- Condition
- Type 2 Diabetes Mellitus
- Intervention (Drug)
- SPIL1033
- Intervention (Drug)
- Placebo
- Lead sponsor
- Sun Pharmaceutical Industries Limited
Record details
- Record id
cardio:ct-nct01406717- Content hash
a1f115675661cd9935bdd1f12e892267a08c8b07894eae2c3e7662546df7f696